Pemetrexed News and Research

RSS
Verastem announces expansion of ongoing COMMAND study in Japan

Verastem announces expansion of ongoing COMMAND study in Japan

NSCLC gene fusion testing, targeted crizotinib – not yet cost effective

NSCLC gene fusion testing, targeted crizotinib – not yet cost effective

Hint of survival benefit with bevacizumabpemetrexed maintenance for NSCLC

Hint of survival benefit with bevacizumabpemetrexed maintenance for NSCLC

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Unusual EGFR mutation should influence advanced NSCLC treatment choice

Lung cancer patients with Del19 mutation benefit most from afatinib

Lung cancer patients with Del19 mutation benefit most from afatinib

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Afatinib ‘first line’ for advanced mutation-positive lung cancer

Unexpected toxicity of pazopanib/pemetrexed in NSCLC halts study

Unexpected toxicity of pazopanib/pemetrexed in NSCLC halts study

Cetuximab fails in second-line combination for recurrent NSCLC

Cetuximab fails in second-line combination for recurrent NSCLC

Pemetrexed, paclitaxel regimens equally effective in NSCLC

Pemetrexed, paclitaxel regimens equally effective in NSCLC

Clinical trials will help to develop treatment and follow-up of COPD patients

Clinical trials will help to develop treatment and follow-up of COPD patients

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Verastem presents positive results from VS-6063 clinical and preclinical studies at 2013 AACR-NCI-EORTC meeting

Intercalated erlotinib/chemotherapy shows mixed results in NSCLC

Intercalated erlotinib/chemotherapy shows mixed results in NSCLC

Personalized treatment may be effective in wild type cancers

Personalized treatment may be effective in wild type cancers

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

Phase III trial shows afatinib offers clinical benefit to patients with EGFR mutation positive NSCLC

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

FDA approves Gilotrif for patients with late stage non-small cell lung cancer

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

OncoGenex plans to initiate OGX-42 Phase 2 trial in patients with advanced squamous cell lung cancer

Phase II study shows effectiveness of Axelar's AXL-003 in treating patients with NSCLC

Phase II study shows effectiveness of Axelar's AXL-003 in treating patients with NSCLC

Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

Boehringer Ingelheim receives FDA Priority Review for afatinib to treat EGFR mutation-positive NSCLC

Crizotinib effectively treats patients with ALK-positive lung cancer

Crizotinib effectively treats patients with ALK-positive lung cancer